Humacyte (HUMA) Non Operating Income (2020 - 2026)

Humacyte (HUMA) has 7 years of Non Operating Income data on file, last reported at $11.3 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at $11.3 million, down 81.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.3 million (down 51.12% YoY), and the FY2025 annual result was $67.3 million, up 296.2% from the prior year.
• Non Operating Income improved to $11.3 million in Q1 2026 per HUMA's latest filing, from $6.0 million in the prior quarter.
• Over five years, Non Operating Income peaked at $62.3 million in Q1 2025 and troughed at -$27.2 million in Q2 2024.
• A 5-year average of $6.2 million and a median of $1.9 million in 2022 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income jumped 2574.99% in 2022, then plunged 848.68% in 2023.
• A 5-year view of Non Operating Income shows it stood at $17.1 million in 2022, then tumbled by 93.7% to $1.1 million in 2023, then jumped by 564.31% to $7.1 million in 2024, then decreased by 15.61% to $6.0 million in 2025, then jumped by 87.6% to $11.3 million in 2026.
• Business Quant data shows HUMA's Non Operating Income at $11.3 million in Q1 2026, $6.0 million in Q4 2025, and $6.9 million in Q3 2025.